Calcitonin, porcine CAS NO.12321-44-7

The primary biological mechanism of Calcitonin, porcine involves its specific binding to and activation of calcitonin receptors (CTR), which are class B G-protein-coupled receptors predominantly expressed on the surface of osteoclasts, renal tubular cells, and certain central nervous system neurons. Upon ligand engagement, the receptor undergoes a conformational change that preferentially couples to Gs proteins, stimulating the activity of adenylate cyclase to increase intracellular cyclic AMP (cAMP) levels, while also potentially engaging Gq proteins to activate the phospholipase C (PLC) beta isoform and elevate inositol triphosphate (IP3). This dual signaling cascade leads to the inhibition of osteoclast motility and ruffled border formation, effectively suppressing bone resorption and reducing the release of calcium and phosphate from the bone matrix into the bloodstream. Concurrently, the activation of CTR in the kidney promotes the excretion of calcium and phosphate by decreasing their reabsorption in the proximal tubules, thereby contributing to the rapid normalization of serum calcium levels through combined skeletal and renal pathways.

Although Calcitonin, porcine is strictly designated for research use and is not a clinical therapeutic agent in most contemporary settings, extensive in vitro and historical clinical studies have validated its significant efficacy in lowering serum calcium and inhibiting bone resorption. Laboratory evaluations confirm that it acts as a potent inhibitor of 1,25-dihydroxyvitamin D3-stimulated osteoclast differentiation and bone resorption, functioning through the targeted disruption of the actin cytoskeleton in osteoclasts to cease bone degradation at nanomolar concentrations. Preclinical and early clinical research demonstrated that parenteral administration of porcine calcitonin effectively reduced elevated serum calcium levels in patients with hypercalcemia of malignancy and provided symptomatic relief from bone pain in conditions like Paget’s disease and osteoporosis, although its potency is notably lower (approximately 1/20th to 1/50th) compared to salmon calcitonin. These findings underscore the efficacy of Calcitonin, porcine as a reliable research reagent for dissecting the fundamental pharmacology of the calcitonin system, validating assay conditions for CTR ligand screening, and providing a mammalian-specific template for understanding species variations in hormone-receptor interactions.

• [✓] A rigorous quality management system
• [✓] Batch traceability and stability data
• [✓] Professional laboratory testing and validation
• [✓] Compliance with international trade standards

Professional and Secure Packaging

Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation. We can also customize packaging according to customer needs.

Shipping Methods

Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.